Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14360593 | 0.78 | TEAD3 (0.43) | L3MBTL1EPHX2TEAD3 | |
| Trifluoroacetic Acid SCHEMBL14360092 | 0.76 | MC1R (0.48) | L3MBTL1 | |
| SCHEMBL14360193 | 0.76 | L3MBTL1 (0.44) | L3MBTL1EPHX2TEAD3 | |
| Trifluoroacetic Acid SCHEMBL1310332 | 0.75 | CYP2C9 (0.36) | L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL31437474 | 0.71 | HDAC3 (0.41) | — | |
| SCHEMBL29439954 | 0.69 | L3MBTL1 (0.46) | L3MBTL1EPHX2TEAD3 | |
| Trifluoroacetic Acid SCHEMBL27579421 | 0.68 | TSHR (0.62) | L3MBTL1 | |
| SCHEMBL17746747 | 0.66 | PPARA (0.52) | L3MBTL1 | |
| SCHEMBL28571966 | 0.66 | HDAC1 (0.68) | — | |
| Trifluoroacetic Acid SCHEMBL31727658 | 0.66 | AGTR2 (0.38) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981952-B2 | Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-05-29 | — | — | US | disclosed |
| EP-2726478-B1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2017-01-11 | — | — | EP | disclosed |
| US-20160237065-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-18 | — | — | US | disclosed |
| US-9353083-B2 | Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-05-31 | — | — | US | disclosed |
| US-20140228342-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-14 | — | — | US | disclosed |
| EP-2726478-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013001030-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237065-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | MC1R, MCHR1, MCHR2 | L3MBTL1 3785/4885EPHX2 1347/4885TEAD3 3731/4885 |
| US-20140228342-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | MC1R, MCHR1, MCHR2 | L3MBTL1 3811/4885EPHX2 1681/4885TEAD3 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.